At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
DNA Ginkgo Bioworks Holdings Inc.
Market Closed 06-05 16:00:00 EDT
8.22
-0.83
-9.17%
盘后8.07
-0.15-1.82%
19:59 EDT
High8.98Low7.94Vol1.52M
Open8.90D1 Closing9.05Amplitude11.51%
Mkt Cap536.97MTradable Cap396.69MTotal Shares65.32M
T/O12.54MT/O Rate3.15%Tradable Shares48.26M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Integrated DNA Technologies enters collaboration with Illumina
TIPRANKS  ·  06-01
Integrated DNA Technologies enters collaboration with Illumina
Elicio Therapeutics publishes data on AMP-DNA adjuvant technology
TIPRANKS  ·  06-01
Elicio Therapeutics publishes data on AMP-DNA adjuvant technology
Trendlines portfolio company Phytolon closes US$ 23.6 million Series B financing
Reuters  ·  05-28
Trendlines portfolio company Phytolon closes US$ 23.6 million Series B financing
Gene Solutions Showcases AI-Powered Multi-Omics Liquid Biopsy Innovations at TJCC 2026: Advancing Precision Oncology in Taiwan
prnewswire  ·  05-22
Gene Solutions Showcases AI-Powered Multi-Omics Liquid Biopsy Innovations at TJCC 2026: Advancing Precision Oncology in Taiwan
Graceful Home Presents DNA Test Results and Marriage Certificate to Address Recent Controversies
Deep News  ·  05-19
Graceful Home Presents DNA Test Results and Marriage Certificate to Address Recent Controversies
Jellyfish Reveals DNA Test Results, Marriage and Birth Certificates to Address Speculation
Deep News  ·  05-19
Jellyfish Reveals DNA Test Results, Marriage and Birth Certificates to Address Speculation
DNA X, Inc. Delays Quarterly Filing After Asset Sale
TIPRANKS  ·  05-16
DNA X, Inc. Delays Quarterly Filing After Asset Sale
Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
prnewswire  ·  05-14
Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
Lotus Unveils Focus 2030 – Reinforcing Brand DNA with an All-New Hybrid-V8 Supercar
GlobeNewswire  ·  05-12
Lotus Unveils Focus 2030 – Reinforcing Brand DNA with an All-New Hybrid-V8 Supercar
Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), Xencor (XNCR) and Alto Neuroscience, Inc. (ANRO)
TIPRANKS  ·  05-11
Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), Xencor (XNCR) and Alto Neuroscience, Inc. (ANRO)
Is Inovio (INO) Turning Fresh DNA Medicine Data Into a More Coherent Investment Story?
Simply Wall St.  ·  05-10
Is Inovio (INO) Turning Fresh DNA Medicine Data Into a More Coherent Investment Story?
Ginkgo Bioworks Q1 revenue falls 49% on restructuring
Reuters  ·  05-08
Ginkgo Bioworks Q1 revenue falls 49% on restructuring
Ginkgo Bioworks reaffirms 2026 expected total cash burn of ($150M)-($125M)
TIPRANKS  ·  05-08
Ginkgo Bioworks reaffirms 2026 expected total cash burn of ($150M)-($125M)
Ginkgo Q1 FY26 net loss narrows 8.36% to $(76) million; revenue drops 49% to $19 million
Reuters  ·  05-08
Ginkgo Q1 FY26 net loss narrows 8.36% to $(76) million; revenue drops 49% to $19 million
Ginkgo Bioworks Holdings Q1 EPS $(1.39) Misses $(1.34) Estimate, Sales $19.474M Miss $41.520M Estimate
Benzinga  ·  05-08
Ginkgo Bioworks Holdings Q1 EPS $(1.39) Misses $(1.34) Estimate, Sales $19.474M Miss $41.520M Estimate
BRIEF-Ginkgo Bioworks Q1 Net Income USD -82.587 Million
Reuters  ·  05-08
BRIEF-Ginkgo Bioworks Q1 Net Income USD -82.587 Million
Ginkgo Bioworks Holdings Inc - Reaffirms 2026 Total Cash Burn Guidance of $(150)-$(125) Mln
THOMSON REUTERS  ·  05-08
Ginkgo Bioworks Holdings Inc - Reaffirms 2026 Total Cash Burn Guidance of $(150)-$(125) Mln
Press Release: Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
Dow Jones  ·  05-08
Press Release: Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
Ginkgo Bioworks Holdings Inc expected to post a loss of $1.08 a share - Earnings Preview
Reuters  ·  05-06
Ginkgo Bioworks Holdings Inc expected to post a loss of $1.08 a share - Earnings Preview
Ginkgo Bioworks to host first-quarter results presentation and Q&A session
Reuters  ·  04-30
Ginkgo Bioworks to host first-quarter results presentation and Q&A session

Introduction

Company Name.
Ginkgo Bioworks Holdings Inc.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Issue price:
--